PT - JOURNAL ARTICLE AU - Weiren Huang AU - Lei Yu AU - Donghua Wen AU - Dong Wei AU - Yangyang Sun AU - Huailong Zhao AU - Yu Ye AU - Wei Chen AU - Yongqiang Zhu AU - Lijun Wang AU - Li Wang AU - Wenjuan Wu AU - Qianqian Zhao AU - Yong Xu AU - Dayong Gu AU - Guohui Nie AU - Dongyi Zhu AU - Zhongliang Guo AU - Xiaoling Ma AU - Liman Niu AU - Yikun Huang AU - Yuchen Liu AU - Bo Peng AU - Renli Zhang AU - Xiuming Zhang AU - Dechang Li AU - Yang Liu AU - Guoliang Yang AU - Lanzheng Liu AU - Yunying Zhou AU - Yunshan Wang AU - Tieying Hou AU - Qiuping Gao AU - Wujiao Li AU - Shuo Chen AU - Xuejiao Hu AU - Mei Han AU - Huajun Zheng AU - Jianping Weng AU - Zhiming Cai AU - Xinxin Zhang AU - Fei Song AU - Guoping Zhao AU - Jin Wang TI - A CRISPR-Cas12a-based specific enhancer for more sensitive detection of SARS-CoV-2 infection AID - 10.1101/2020.06.02.20119735 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.02.20119735 4099 - http://medrxiv.org/content/early/2020/06/05/2020.06.02.20119735.short 4100 - http://medrxiv.org/content/early/2020/06/05/2020.06.02.20119735.full AB - High Ct-values falling in the grey zone are frequently encountered in SARS-CoV-2 detection by real-time reverse transcription PCR (rRT-PCR) and have brought urgent challenges in diagnosis of samples with low viral load. Based on the single-stranded DNA reporter trans-cleavage activity by Cas12a upon target DNA recognition, we create a Specific Enhancer for detection of PCR-amplified Nucleic Acids (SENA) to confirm SARS-CoV-2 detection through specifically targeting its rRT-PCR amplicons. SENA is highly sensitive, with its limit of detection being at least 2 copies/reaction lower than that of the corresponding rRT-PCR, and highly specific, which identifies both false-negative and false-positive cases in clinic applications. SENA provides effective confirmation for nucleic acid amplification-based molecular diagnosis, and may immediately eliminate the uncertainty problems of rRT-PCR in SARS-CoV-2 clinic detection.One Sentence Summary CRISPR-Cas12a-based COVID-19 diagnosis.Competing Interest StatementG.Z. and J.W. are cofounders of Tolo Biotechnology Co., Ltd. W.H., G.Z. and J.W. have filed patent applications relating to the work in this manuscript.Funding StatementJ.W. is supported by the National Natural Science Foundation of China (31922046); W.H. is supported by the National Key R&D Program of China (2019YFA0906000) and NSFC (81772737); D.W. is supported by NSFC (81972830) and Shanghai "Rising Stars of Medical Talent" Youth Development Program-Clinical Laboratory Practitioners Program; F.S. is supported by NSFC (31670757); G.Z. is supported by the Strategic Priority Research Program of the Chinese Academy of Sciences (XDB19040200).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The human pharyngeal swab samples were collected from residual samples that had been obtained for clinical respiratory virus detection. All procedures complied with the Measures for the Ethical Review of Biomedical Research Involving Human Subjects issued by the National Health and Family Planning Commission of The People's Republic of China. All protocols were approved by the Ethics Committees of Ruijin Hospital, Dongfang Hospital and Shenzhen Second People's Hospital. All procedures were performed in biosafety level 2 facilities.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available in the main text or the supplementary materials.